Interleukin-23 inhibitors demonstrate high effectiveness in the treatment of a real-world cohort of 82 psoriatic patients regardless of the HLA-Cw6 status

Dermatol Ther. 2022 Oct;35(10):e15741. doi: 10.1111/dth.15741. Epub 2022 Aug 9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Arthritis, Psoriatic*
  • HLA-C Antigens / genetics
  • Humans
  • Interleukin Inhibitors
  • Interleukin-23
  • Psoriasis* / drug therapy

Substances

  • HLA-C Antigens
  • HLA-C*06 antigen
  • Interleukin Inhibitors
  • Interleukin-23